A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens
Philadelphia chromosome-positive acute lymphoblastic leukemia (PH + ALL) is the most common cytogenetic abnormality of B-ALL in adults and is associated with poor prognosis. Previously, the only curative treatment option in PH + ALL was allogeneic hematopoietic stem cell transplantation (Allo-HSCT)....
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2024.2335856 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846126634790289408 |
|---|---|
| author | Zhen-Yu Xiong Yao-Jia Shen Shi-Zhong Zhang Hong-Hu Zhu |
| author_facet | Zhen-Yu Xiong Yao-Jia Shen Shi-Zhong Zhang Hong-Hu Zhu |
| author_sort | Zhen-Yu Xiong |
| collection | DOAJ |
| description | Philadelphia chromosome-positive acute lymphoblastic leukemia (PH + ALL) is the most common cytogenetic abnormality of B-ALL in adults and is associated with poor prognosis. Previously, the only curative treatment option in PH + ALL was allogeneic hematopoietic stem cell transplantation (Allo-HSCT). Since 2000, targeted therapy combined with chemotherapy, represented by the tyrosine kinase inhibitor Imatinib, has become the first-line treatment for PH + ALL. Currently, the remission rate and survival rate of Imatinib are superior to those of simple chemotherapy, and it can also improve the efficacy of transplantation. More recently, some innovative immune-targeted therapy greatly improved the prognosis of PH + ALL, such as Blinatumomab and Inotuzumab Ozogamicin. For patients with ABL1 mutations and those who have relapsed or are refractory to other treatments, targeted oral small molecule drugs, monoclonal antibodies, Bispecific T cell Engagers (BiTE), and chimeric antigen receptor (CAR) T cells immunotherapy are emerging as potential treatment options. These new therapeutic interventions are changing the treatment landscape for PH + ALL. In summary, this review discusses the current advancements in targeted therapeutic agents shift in the treatment strategy of PH + ALL towards using more tolerable chemotherapy-free induction and consolidation regimens confers better disease outcomes and might obviate the need for HSCT. |
| format | Article |
| id | doaj-art-2ab941d870f746c88dd5fc72bb30c9d3 |
| institution | Kabale University |
| issn | 1607-8454 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj-art-2ab941d870f746c88dd5fc72bb30c9d32024-12-12T15:08:53ZengTaylor & Francis GroupHematology1607-84542024-12-0129110.1080/16078454.2024.2335856A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimensZhen-Yu Xiong0Yao-Jia Shen1Shi-Zhong Zhang2Hong-Hu Zhu3Third-Grade Pharmacological Laboratory on Chinese Medicine Approved by State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang, People’s Republic of ChinaDepartment of Hematology, Children’s Hospital of Zhejiang University School of Medicine, Hangzhou, People’s Republic of ChinaThird-Grade Pharmacological Laboratory on Chinese Medicine Approved by State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang, People’s Republic of ChinaThird-Grade Pharmacological Laboratory on Chinese Medicine Approved by State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang, People’s Republic of ChinaPhiladelphia chromosome-positive acute lymphoblastic leukemia (PH + ALL) is the most common cytogenetic abnormality of B-ALL in adults and is associated with poor prognosis. Previously, the only curative treatment option in PH + ALL was allogeneic hematopoietic stem cell transplantation (Allo-HSCT). Since 2000, targeted therapy combined with chemotherapy, represented by the tyrosine kinase inhibitor Imatinib, has become the first-line treatment for PH + ALL. Currently, the remission rate and survival rate of Imatinib are superior to those of simple chemotherapy, and it can also improve the efficacy of transplantation. More recently, some innovative immune-targeted therapy greatly improved the prognosis of PH + ALL, such as Blinatumomab and Inotuzumab Ozogamicin. For patients with ABL1 mutations and those who have relapsed or are refractory to other treatments, targeted oral small molecule drugs, monoclonal antibodies, Bispecific T cell Engagers (BiTE), and chimeric antigen receptor (CAR) T cells immunotherapy are emerging as potential treatment options. These new therapeutic interventions are changing the treatment landscape for PH + ALL. In summary, this review discusses the current advancements in targeted therapeutic agents shift in the treatment strategy of PH + ALL towards using more tolerable chemotherapy-free induction and consolidation regimens confers better disease outcomes and might obviate the need for HSCT.https://www.tandfonline.com/doi/10.1080/16078454.2024.2335856BCR-ABL1acute lymphoblastic leukemiaPhiladelphia chromosometyrosine kinase inhibitorsimmunotherapy |
| spellingShingle | Zhen-Yu Xiong Yao-Jia Shen Shi-Zhong Zhang Hong-Hu Zhu A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens Hematology BCR-ABL1 acute lymphoblastic leukemia Philadelphia chromosome tyrosine kinase inhibitors immunotherapy |
| title | A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens |
| title_full | A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens |
| title_fullStr | A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens |
| title_full_unstemmed | A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens |
| title_short | A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens |
| title_sort | review of immunotargeted therapy for philadelphia chromosome positive acute lymphoblastic leukaemia making progress in chemotherapy free regimens |
| topic | BCR-ABL1 acute lymphoblastic leukemia Philadelphia chromosome tyrosine kinase inhibitors immunotherapy |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2024.2335856 |
| work_keys_str_mv | AT zhenyuxiong areviewofimmunotargetedtherapyforphiladelphiachromosomepositiveacutelymphoblasticleukaemiamakingprogressinchemotherapyfreeregimens AT yaojiashen areviewofimmunotargetedtherapyforphiladelphiachromosomepositiveacutelymphoblasticleukaemiamakingprogressinchemotherapyfreeregimens AT shizhongzhang areviewofimmunotargetedtherapyforphiladelphiachromosomepositiveacutelymphoblasticleukaemiamakingprogressinchemotherapyfreeregimens AT honghuzhu areviewofimmunotargetedtherapyforphiladelphiachromosomepositiveacutelymphoblasticleukaemiamakingprogressinchemotherapyfreeregimens AT zhenyuxiong reviewofimmunotargetedtherapyforphiladelphiachromosomepositiveacutelymphoblasticleukaemiamakingprogressinchemotherapyfreeregimens AT yaojiashen reviewofimmunotargetedtherapyforphiladelphiachromosomepositiveacutelymphoblasticleukaemiamakingprogressinchemotherapyfreeregimens AT shizhongzhang reviewofimmunotargetedtherapyforphiladelphiachromosomepositiveacutelymphoblasticleukaemiamakingprogressinchemotherapyfreeregimens AT honghuzhu reviewofimmunotargetedtherapyforphiladelphiachromosomepositiveacutelymphoblasticleukaemiamakingprogressinchemotherapyfreeregimens |